Evidence map›Paper›PMID 26518062›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2015

Time trend analysis of cervical high-risk human papillomavirus (HPV) in HIV-infected women in an urban cohort from Rio de Janeiro, Brazil: the rise of non-16/18 HPV.

Mary C Cambou, José Eduardo Levi, Jordan E Lake, Angela de Andrade, Emilia M Jalil, Fabio Russomano, Mônica Derrico, Valdilea G Veloso, Ruth K Friedman, Paula M Luz and 1 more

Abstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Cervical Cancer Screening and Treatment Algorithms Using Human Papillomavirus Testing-Lessons Learnt from a South African Pilot Randomized Controlled Trial.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mary C CambouDepartment of Medicine, Division of Infectious Diseases, Program in Global Health, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, CHS 37-121, Los Angeles, CA 90095, USA; Department of Internal Medicine, Montefiore University Hospital of Albert Einstein College of Medicine, Bronx, New York, USA. Electronic address: mcambou@montefiore.org.
José Eduardo LeviVirology Laboratory, Instituto de Medicina Tropical, Universidade de São Paulo, São Paulo, SP, Brazil.
Jordan E LakeDepartment of Medicine, Division of Infectious Diseases, Program in Global Health, UCLA David Geffen School of Medicine, 10833 Le Conte Avenue, CHS 37-121, Los Angeles, CA 90095, USA.
Angela de AndradeInstituto Nacional de Infectologia Evandro Chagas (IPEC), Fundação Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, Brazil.
Emilia M JalilInstituto Nacional de Infectologia Evandro Chagas (IPEC), Fundação Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, Brazil.
Fabio RussomanoInstituto Fernandes Figueira, Fiocruz, Rio de Janeiro, RJ, Brazil.
Mônica DerricoInstituto Nacional de Infectologia Evandro Chagas (IPEC), Fundação Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, Brazil.
Valdilea G VelosoInstituto Nacional de Infectologia Evandro Chagas (IPEC), Fundação Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, Brazil.
Ruth K FriedmanInstituto Nacional de Infectologia Evandro Chagas (IPEC), Fundação Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, Brazil.
Paula M LuzInstituto Nacional de Infectologia Evandro Chagas (IPEC), Fundação Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, Brazil.
Beatriz GrinsztejnInstituto Nacional de Infectologia Evandro Chagas (IPEC), Fundação Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, Brazil.

Funding

The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
South American Program in HIV Prevention Research (SAPHIR)R25MH087222 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JESSE LAWTON CLARK, Karin Nielsen · 2011 to 2026
$3.9M
Inflammation, Fibrosis and End-Organ Disease in HIV-Infected AdultsK23AI110532 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LAKE, JORDAN E · 2014 to 2018
$937k
NIAID NIH HHS K23 AI110532NIAID NIH HHS K23AI110532NIAID NIH HHS UM1 AI069476NIMH NIH HHS R25 MH087222
6 · The paper itself

Abstract

objectivesHIV-infected women are at increased risk of human papillomavirus (HPV) infection. Time trends in annual prevalences of cervical high-risk human papillomavirus (HR-HPV) genotypes among a non-vaccinated, HIV-infected female cohort in urban Brazil were assessed for the period 2006-2012.

methodsCervical specimens were collected for HPV genotyping yearly between January 2006 and December 2012 in a cross-sectional analysis of participants aged ≥18 years enrolled in the Women's HIV Cohort at Fiocruz in Rio de Janeiro, Brazil. Age-adjusted generalized estimating equation models with an exchangeable matrix were used to estimate odds ratios (OR) and 95% confidence intervals (CI) for annual HPV positivity (reference year: 2006).

resultsAmong the 590 participants, the median age across all study years ranged from 35.5 to 40.0 years. The prevalence of any HR-HPV was ≥53% every year; prevalences of HR-HPV 16, 58, 59, and 68 were ≥24% in at least 1 year. The odds of HPV 16 and 68 decreased in 2012. HPV 58 prevalence followed a U-shape, beginning and ending at >20%. HPV 59 prevalence followed a linear trend, with increased odds in 2012 (OR 16.0, 95% CI 3.8-67.3; Bonferroni-adjusted p-value <0.01).

conclusionsThe prevalences of HR-HPV 58, 59, and 68 were high in this cohort. Given current HR-HPV vaccine coverage and availability, further investigations are needed to optimize vaccine recommendations for this population.

Indexed as

AdultBrazilCohort StudiesCross-Sectional StudiesFemaleGenotypeHIV InfectionsHumansMiddle AgedOdds RatioPapillomaviridaePapillomavirus InfectionsPrevalenceRisk FactorsTime FactorsUrban PopulationCervical HPVEpidemiologyHigh-risk HPVHIVHPV vaccineWomen

Identifiers

PMID26518062
PMCPMC4697734

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.